scholarly journals Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer

2016 ◽  
Vol 5 (4) ◽  
pp. 224-230 ◽  
Author(s):  
Giacomo Sturniolo ◽  
Carles Zafon ◽  
Mariacarla Moleti ◽  
Josep Castellví ◽  
Francesco Vermiglio ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Progesterone Receptor ◽  
Papillary Thyroid Cancer ◽  
Estrogen Receptor Α ◽  
Papillary Thyroid ◽  
Immunohistochemical Expression

scholarly journals Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer

2015 ◽  
Vol 173 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Guia Vannucchi ◽  
Simone De Leo ◽  
Michela Perrino ◽  
Stefania Rossi ◽  
Delfina Tosi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Progesterone Receptor ◽  
Papillary Thyroid Cancer ◽  
Reproductive Factors ◽  
Estrogen Receptor Α ◽  
Receptor Expression ◽  
Biological Behavior ◽  
Papillary Thyroid ◽  
Primary Tumors ◽  
Molecular Features

BackgroundThyroid cancer is highly prevalent in women during the fertile age, which suggests a possible impact of hormonal and reproductive factors.MethodsWe studied the expression of estrogen receptor α (ERα or ESR1) and progesterone receptor (PR or PGR) in 182 female and male patients with papillary thyroid cancer and correlated it to clinical and molecular features.ResultsERα and PR expression was found in 66.5 and 75.8% of patients respectively and was significantly correlated with larger tumor size and with a non-incidental diagnosis. Moreover, a trend toward a higher prevalence of local metastases was observed in ER- and PR-expressing tumors, which possibly indicates a more aggressive behavior. Interestingly, the occurrence of the ‘receptor conversion’ phenomenon, which has already been reported to have a negative prognostic effect in breast cancer, was demonstrated for the first time in thyroid tumors. Indeed, almost all of the ERα-positive primary tumors analyzed had ERα-negative metastatic lymph nodes. At the genetic analyses,BRAFV600Emutation was detected in 23.2% of the tumors and had a higher prevalence in larger tumors and in those with a stronger ERα or PR staining.ConclusionsThe whole of the findings reported in the present study argue for an association between ERα and PR sex hormone receptor expression and a more aggressive presentation. Although no impact on outcome was found, the evaluation of ERα and PR receptor expression could add insights into the biological behavior of tumors and could modify the follow-up, particularly in fertile women affected with persistent disease.

scholarly journals Organoid Cultures Derived From Patients With Papillary Thyroid Cancer

2021 ◽  
Author(s):  
Dong Chen ◽  
Yawen Tan ◽  
Zhichao Li ◽  
Wujiao Li ◽  
Lei Yu ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Treatment Options ◽  
Estrogen Receptor Α ◽  
Patient Specific ◽  
Preclinical Model ◽  
Papillary Thyroid ◽  
Promote Cell Proliferation

Abstract Context Papillary thyroid cancer (PTC) has been one of the most frequent endocrine malignancies around the world. Although most PTC patients have a favorable prognosis, a subgroup of patients die, especially when disease recurrence occurs. There is a pressing need for clinically relevant preclinical thyroid cancer models for personalized therapy because of the lack of in vitro models that faithfully represent the biology of the parental tumors. Objective To understand thyroid cancer and translate this knowledge to clinical applications, patient-derived PTC organoids as a promising new preclinical model were established. Methods Surgically resected PTC primary tissues were dissociated and processed for organoid derivation. Tumor organoids were subsequently subjected to histological characterization, DNA sequencing, drug screen, and cell proliferation assay, respectively. Results We describe a 3-dimensional culture system for the long-term expansion of patient-derived PTC organoid lines. Notably, PTC organoids preserve the histopathological profiles and genomic heterogeneity of the originating tumors. Drug sensitivity assays of PTC organoids demonstrate patient-specific drug responses, and large correlations with the respective mutational profiles. Estradiol was shown to promote cell proliferation of PTC organoids in the presence of estrogen receptor α (ERα), regardless of the expression of ERβ and G protein–coupled ER. Conclusion These data suggest that these newly developed PTC-derived organoids may be an excellent preclinical model for studying clinical response to anticancer drugs in a personalized way, as well as provide a potential strategy to develop prevention and treatment options for thyroid cancer with ERα-specific antagonists.

A Postmenopausal Woman with Gross Cystic Disease Fluid Protein-15 and Estrogen Receptor-Positive Recurrence of Papillary Thyroid Cancer

Thyroid ◽  
2010 ◽  
Vol 20 (12) ◽  
pp. 1413-1417 ◽  
Author(s):  
Amanda Winters ◽  
Paul Friedlander ◽  
Bernard M. Jaffe ◽  
Mohamed Abdel Khalek ◽  
Krzysztof Moroz ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Postmenopausal Woman ◽  
Papillary Thyroid Cancer ◽  
Cystic Disease ◽  
Papillary Thyroid ◽  
Positive Recurrence ◽  
Estrogen Receptor Positive ◽  
Cystic Disease Fluid Protein

scholarly journals Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Shucai Yang ◽  
Zhongqin Gong ◽  
Zhimin Liu ◽  
Minghui Wei ◽  
Lingbin Xue ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Cancer Cells ◽  
Papillary Thyroid Cancer ◽  
Estrogen Receptor Alpha ◽  
Peroxisome Proliferator ◽  
Papillary Thyroid ◽  
Peroxisome Proliferator Activated Receptor ◽  
Receptor Alpha ◽  
Induced Apoptosis

PurposeThe inhibition of estrogen receptor alpha (ERα) or the activation of ERβ can inhibit papillary thyroid cancer (PTC), but the precise mechanism is not known. We aimed to explore the role of ERα and ERβ on the production of endogenous peroxisome proliferator-activated receptor gamma (PPARγ) ligands in PTC.Methods2 PTC cell lines, 32 pairs of PTC tissues and matched normal thyroid tissues were used in this study. The levels of endogenous PPARγ ligands 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), 13-S-hydroxyoctadecadienoic acid (13(S)-HODE), and15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) were measured by ELISA.ResultsThe levels of PGJ2 and 15(S)-HETE were significantly reduced in PTC, but 13(S)-HODE was not changed. Activation of ERα or inhibition of ERβ significantly downregulated the production of PGJ2, 15(S)-HETE and 13(S)-HODE, whereas inhibition of ERα or activation of ERβ markedly upregulated the production of these three ligands. Application of endogenous PPARγ ligands inhibited growth, induced apoptosis of cancer cells, and promoted the efficacy of chemotherapy.ConclusionThe levels of endogenous PPARγ ligands PGJ2 and 15(S)-HETE are significantly decreased in PTC. The inhibition of ERα or activation of ERβ can inhibit PTC by stimulating the production of endogenous PPARγ ligands to induce apoptosis in cancer cells.

Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause

Surgery ◽  
2018 ◽  
Vol 163 (1) ◽  
pp. 143-149 ◽  
Author(s):  
Gustavo A. Rubio ◽  
Paola Catanuto ◽  
Marilyn K. Glassberg ◽  
John I. Lew ◽  
Sharon J. Elliot
Keyword(s):  
Estrogen Receptor ◽  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Receptor Subtype ◽  
Papillary Thyroid

Immunohistochemical Expression of Bcl-2, Ki-67, and p21 in Patients with Papillary Thyroid Cancer

Tumor Biology ◽  
2005 ◽  
Vol 26 (1) ◽  
pp. 50-56 ◽  
Author(s):  
Päivi Siironen ◽  
Stig Nordling ◽  
Johanna Louhimo ◽  
Reijo Haapiainen ◽  
Caj Haglund
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Immunohistochemical Expression ◽  
Ki 67
Sign in / Sign up

Export Citation Format

Share Document